Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
3(30%)
Results Posted
100%(6 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_2
4
40%
Ph phase_1
1
10%
Ph phase_4
1
10%
Ph phase_3
3
30%

Phase Distribution

1

Early Stage

4

Mid Stage

4

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
4(44.4%)
Phase 3Large-scale testing
3(33.3%)
Phase 4Post-market surveillance
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

3

trials recruiting

Total Trials

10

all time

Status Distribution
Active(3)
Completed(6)
Terminated(1)

Detailed Status

Completed6
Recruiting3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
3
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (11.1%)
Phase 24 (44.4%)
Phase 33 (33.3%)
Phase 41 (11.1%)

Trials by Status

completed660%
terminated110%
recruiting330%

Recent Activity

3 active trials
Showing 5 of 10
recruitingphase_1

Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids

NCT05588323
completedphase_4

Prophylactic Use of Naldemedine on Opioid-induced Nausea and Vomiting in Patients With Cancer: POSEIDON Study

NCT07038551
recruiting

Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation

NCT03720613
recruitingphase_2

The Effect of Naldemedine on Opioid-induced Bowel Dysfunction

NCT06334198
terminatedphase_2

A Study of Naldemedine in Participants Undergoing Surgeries That Include a Bowel Resection or Bowel Transection

NCT04355169
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT05588323Phase 1

Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids

Recruiting
NCT07038551Phase 4

Prophylactic Use of Naldemedine on Opioid-induced Nausea and Vomiting in Patients With Cancer: POSEIDON Study

Completed
NCT03720613

Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation

Recruiting
NCT06334198Phase 2

The Effect of Naldemedine on Opioid-induced Bowel Dysfunction

Recruiting
NCT04355169Phase 2

A Study of Naldemedine in Participants Undergoing Surgeries That Include a Bowel Resection or Bowel Transection

Terminated
NCT01965652Phase 3

Long Term Safety of Naldemedine

Completed
NCT01443403Phase 2

A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy

Completed
NCT01965158Phase 3

Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation

Completed
NCT01122030Phase 2

Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain

Completed
NCT01993940Phase 3

Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10